PT  - JOURNAL ARTICLE
AU  - Ali, Hamad
AU  - Alshukry, Abdullah
AU  - Abbas, Mohammad Bu
AU  - Ali, Yaseen
AU  - Alahmad, Barrak
AU  - Al-Shammari, Abdullah A.
AU  - Abu-Farha, Mohammad
AU  - AbuBaker, Jehad
AU  - Devarajan, Sriraman
AU  - Dashti, Ali A.
AU  - Al-Mulla, Fahd
TI  - Clinical Characteristics and Outcomes of Diabetic COVID-19 patients in Kuwait
AID  - 10.1101/2020.08.20.20178525
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.20.20178525
4099  - http://medrxiv.org/content/early/2020/08/22/2020.08.20.20178525.short
4100  - http://medrxiv.org/content/early/2020/08/22/2020.08.20.20178525.full
AB  - Background Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in 2019 and rapidly turned into a global pandemic, resulting in what is now known as Coronavirus Disease 2019 (COVID-19). COVID-19 has a highly variable clinical presentation, ranging from asymptomatic to severe respiratory symptoms and death. Diabetes seems to be one of the main comorbidities contributing to a worse COVID-19 outcome.Methods In this single-center, retrospective study of 417 consecutive COVID-19 patients in Kuwait, we analyze and compare disease severity, outcome, associated complications, and clinical laboratory findings between diabetic and non-diabetic COVID-19 patients.Results COVID-19 patients with diabetes had a higher prevalence of comorbidities, such as hypertension, higher levels of inflammatory markers, lower estimated glomerular filtration rate, and a higher incidence of complications. All of these factors could lead to more severe outcomes and higher mortality than non-diabetic COVID-19 patients.Conclusion Diabetes could be a major contributor to COVID-19 worsening outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was obtained for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Standing Committee for Coordination of Health and Medical Research at the Ministry of Health in Kuwait reviewed and approved this retrospective study (Institutional Review Board 2020/1404). The Standing Committee waived the requirement for written informed consent because of the urgency of data collection and the exceptional nature of the disease. All procedures involving human participants were performed following the relevant guidelines and regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData presented in this study was made available on springer nature data depository. https://doi.org/10.6084/m9.figshare.12567881.v1.